FindTrial
Sign In

Double blind, randomised controlled cross over trial comparing the antihypertensive effects of amiloride and spironolactone in black hypertensives with and without the T594M mutation

Double blind, randomised controlled cross over trial comparing the antihypertensive effects of amiloride and spironolactone in black hypertensives with and without the T594M mutation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN21821912
Enrollment
Unknown
Registered
2002-03-08
Start date
2002-01-01
Completion date
Unknown
Last updated
2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Hypertension

Interventions

1. Amiloride 5 mg bd for 2 weeks, increased to 10 mg bd for further 6 weeks. Then cross over to spironolactone as below, then to a combination of amiloride 5 mg bd plus spironolactone 25 mg bd 2. Spir

Sponsors

British Heart Foundation (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Hypertensives of African origin 2. Subjects with the T594M polymorphism and controls with the wild-type sodium channel

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026